Peter S. Dragovich
California Institute of Technology
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Peter S. Dragovich.
Tetrahedron Letters | 1989
Andrew G. Myers; Mian M. Alauddin; Mary Ann M. Fuhry; Peter S. Dragovich; Nathaniel S. Finney; Philip M. Harrington
Abstract (Z)-Ethyl 2,3-dibromopropenoate, readily available in multigram quantities, undergoes selective replacement of the β-bromide in coupling reactions with trimethylsilylacetylene to produce the (Z)-enyne 2. This product may be further elaborated to various functionalized enynes of defined geometry or may be coupled with a second acetylenic reactant to produce (Z)-enediynes.
Bioorganic & Medicinal Chemistry Letters | 2009
Frank Ruebsam; Douglas E. Murphy; Chinh V. Tran; Lian-Sheng Li; Jingjing Zhao; Peter S. Dragovich; Helen M. McGuire; Alan X. Xiang; Zhongxiang Sun; Benjamin K. Ayida; Julie K. Blazel; Sun Hee Kim; Yuefen Zhou; Qing Han; Charles R. Kissinger; Stephen E. Webber; Richard E. Showalter; Amit M. Shah; Mei Tsan; Rupal Patel; Peggy A. Thompson; Laurie A. LeBrun; Huiying J. Hou; Ruhi Kamran; Maria V. Sergeeva; Darian M. Bartkowski; Thomas G. Nolan; Daniel A. Norris; Julia Khandurina; Jennifer Brooks
A novel series of non-nucleoside small molecules containing a tricyclic dihydropyridinone structural motif was identified as potent HCV NS5B polymerase inhibitors. Driven by structure-based design and building on our previous efforts in related series of molecules, we undertook extensive SAR studies, in which we identified a number of metabolically stable and very potent compounds in genotype 1a and 1b replicon assays. This work culminated in the discovery of several inhibitors, which combined potent in vitro antiviral activity against both 1a and 1b genotypes, metabolic stability, good oral bioavailability, and high C(12) (PO)/EC(50) ratios.
Bioorganic & Medicinal Chemistry Letters | 2009
Frank Ruebsam; Chinh V. Tran; Lian-Sheng Li; Sun Hee Kim; Alan X. Xiang; Yuefen Zhou; Julie K. Blazel; Zhongxiang Sun; Peter S. Dragovich; Jingjing Zhao; Helen M. McGuire; Douglas E. Murphy; Martin T. Tran; David Archer Ellis; Alberto Gobbi; Richard E. Showalter; Stephen E. Webber; Amit M. Shah; Mei Tsan; Rupal Patel; Laurie A. LeBrun; Huiying J. Hou; Ruhi Kamran; Maria V. Sergeeva; Darian M. Bartkowski; Thomas G. Nolan; Daniel A. Norris; Leo Kirkovsky
5,6-Dihydro-1H-pyridin-2-one analogs were discovered as a novel class of inhibitors of genotype 1 HCV NS5B polymerase. Among these, compound 4ad displayed potent inhibitory activities in biochemical and replicon assays (IC(50) (1b)<10nM; IC(50) (1a)<25nM, EC(50) (1b)=16nM), good in vitro DMPK properties, as well as moderate oral bioavailability in monkeys (F=24%).
Bioorganic & Medicinal Chemistry Letters | 2008
Maria V. Sergeeva; Yuefen Zhou; Darian M. Bartkowski; Thomas G. Nolan; Daniel A. Norris; Ellen Okamoto; Leo Kirkovsky; Ruhi Kamran; Laurie A. LeBrun; Mei Tsan; Rupal Patel; Amit M. Shah; Matthew Lardy; Alberto Gobbi; Lian-Sheng Li; Jingjing Zhao; Thomas M. Bertolini; Zhongxiang Sun; Douglas E. Murphy; Stephen E. Webber; Peter S. Dragovich
5-Hydroxy-3(2H)-pyridazinone derivatives were investigated as potent inhibitors of genotype 1 HCV NS5B polymerase focusing on the optimization of their drug metabolism and pharmacokinetics (DMPK) profiles. This investigation led to the discovery of potent inhibitors with improved DMPK properties.
Bioorganic & Medicinal Chemistry Letters | 2008
David Archer Ellis; Julie K. Blazel; Stephen E. Webber; Chinh V. Tran; Peter S. Dragovich; Zhongxiang Sun; Frank Ruebsam; Helen M. McGuire; Alan X. Xiang; Jingjing Zhao; Lian-Sheng Li; Yuefen Zhou; Qing Han; Charles R. Kissinger; Richard E. Showalter; Matthew Lardy; Amit M. Shah; Mei Tsan; Rupal Patel; Laurie A. LeBrun; Ruhi Kamran; Darian M. Bartkowski; Thomas G. Nolan; Daniel A. Norris; Maria V. Sergeeva; Leo Kirkovsky
4-(1,1-Dioxo-1,4-dihydro-1lambda(6)-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-one analogs were discovered as a novel class of inhibitors of HCV NS5B polymerase. Structure-based design led to the identification of compound 3a that displayed potent inhibitory activities in biochemical and replicon assays (1b IC(50)<10 nM; 1b EC(50)=1.1 nM) as well as good stability toward human liver microsomes (HLM t(1/2)>60 min).
Synthetic Communications | 2008
Peter S. Dragovich; Douglas E. Murphy; Chinh V. Tran; Frank Ruebsam
Abstract A novel synthesis of 2-amino-5-methanesulfonylaminobenzenesulfonamide is described. This preparation begins with readily available 4-nitroaniline and proceeds through five steps (isolations) in 41% overall yield. The described chemistry is conducted on a 50- to 100-g scale and does not require extractive workup procedures or chromatographic purifications.
Journal of the American Chemical Society | 1992
Andrew G. Myers; Peter S. Dragovich
Journal of the American Chemical Society | 1989
Andrew G. Myers; Peter S. Dragovich
Journal of the American Chemical Society | 1992
Andrew G. Myers; Peter S. Dragovich
Journal of the American Chemical Society | 1993
Andrew G. Myers; Peter S. Dragovich